|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,758,549: Lumateperone Tosesylate Formulation
This report provides a detailed analysis of U.S. Patent 10,758,549, focusing on its scope, claims, and the surrounding patent landscape for the drug lumateperone tosilate. This patent protects a specific salt form of lumateperone, designated as lumateperone tosilate, and its use in treating central nervous system disorders.
What is the Subject Matter of U.S. Patent 10,758,549?
U.S. Patent 10,758,549, titled "LUMATEPERONE TOSYLATE AND USE THEREOF," issued on September 6, 2022. The patent was assigned to Intra-Cellular Therapies, Inc. The core of the patent is the crystalline form of lumateperone tosilate, specifically Form A, and its pharmaceutical compositions.
The patent claims cover:
- A specific crystalline form of lumateperone tosilate (Form A): This is defined by its X-ray powder diffraction (XRPD) pattern, differential scanning calorimetry (DSC) profile, and other physical characteristics.
- Pharmaceutical compositions containing lumateperone tosilate: These compositions are intended for the treatment of central nervous system (CNS) disorders.
- Methods of treating CNS disorders: The patent outlines methods of using lumateperone tosilate for treating conditions such as schizophrenia, bipolar depression, and major depressive disorder.
The described crystalline form, Form A, is characterized by specific peak positions and intensities in its XRPD pattern. For example, it possesses characteristic peaks at approximately 8.7°, 12.5°, 13.8°, 14.9°, 17.3°, and 19.0° 2θ. The DSC analysis shows a specific endotherm with a peak temperature around 197°C.
The specification details the synthesis of lumateperone tosilate by reacting lumateperone with p-toluenesulfonic acid. The focus on Form A suggests that this specific crystalline structure offers advantages, potentially related to stability, bioavailability, or manufacturing.
What are the Key Claims in Patent 10,758,549?
The patent contains multiple claims, with independent claims defining the core subject matter. Key claims include:
- Claim 1: This claim defines a crystalline form of lumateperone tosilate, designated as Form A, characterized by specific peaks in its XRPD pattern. This is the foundational claim protecting the specific crystalline entity.
- Claim 7: This claim covers a pharmaceutical composition comprising lumateperone tosilate (Form A) and at least one pharmaceutically acceptable carrier. This broadens the protection to include formulations for drug delivery.
- Claim 13: This claim describes a method of treating schizophrenia, comprising administering a therapeutically effective amount of lumateperone tosilate to a subject. This claim targets the therapeutic application of the patented compound.
- Claim 14: Similar to Claim 13, this claim addresses the method of treating bipolar depression.
- Claim 15: This claim pertains to the method of treating major depressive disorder.
Dependent claims further refine these aspects, for instance, by specifying particular carriers or dosages within the pharmaceutical compositions or methods of treatment. The claims are designed to capture the distinct crystalline form and its therapeutic use, aiming to provide comprehensive market exclusivity.
How Does Patent 10,758,549 Protect Lumateperone Tosylate?
The patent protects lumateperone tosilate through several mechanisms:
- Composition of Matter Claims: While the base molecule lumateperone is known, Patent 10,758,549 specifically claims the tosilate salt form, and crucially, a particular crystalline form (Form A) of this salt. This is a significant form of protection as it covers the specific physical manifestation of the drug substance.
- Formulation Claims: The patent protects pharmaceutical compositions containing lumateperone tosilate. This prevents competitors from creating generic versions by simply using different excipients or formulation techniques as long as the active pharmaceutical ingredient (API) is the patented lumateperone tosilate.
- Method of Use Claims: The patent claims specific methods of treating CNS disorders using lumateperone tosilate. This provides protection against competitors marketing generic versions of the drug for these specific indications, even if they develop a non-infringing formulation or crystalline form of the API.
The issuance of this patent suggests that Intra-Cellular Therapies, Inc. has successfully demonstrated novelty, non-obviousness, and utility for lumateperone tosilate and its specific crystalline form for treating the claimed indications.
What is the Patent Landscape for Lumateperone and Related Compounds?
The patent landscape for lumateperone and its derivatives is complex, with multiple patents covering different aspects of the drug, its synthesis, and its therapeutic applications. U.S. Patent 10,758,549 is one of several patents protecting lumateperone.
Key Patents and Areas of Protection:
- Composition of Matter Patents for Lumateperone: Earlier patents likely cover the lumateperone molecule itself. For example, U.S. Patent 8,071,600 and U.S. Patent 8,921,550, also assigned to Intra-Cellular Therapies, Inc., cover lumateperone and its use in treating CNS disorders. These foundational patents are critical for establishing initial market exclusivity.
- Salt and Polymorph Patents: U.S. Patent 10,758,549 falls into this category, specifically protecting the tosilate salt and its crystalline Form A. Other patents may exist or be filed covering different salt forms or polymorphs of lumateperone, each offering potentially distinct periods of exclusivity.
- Synthesis Patents: Patents may exist covering novel or improved methods for synthesizing lumateperone or its salts. These can block competitors from using efficient or cost-effective manufacturing processes.
- Formulation and Delivery Patents: Beyond the compositions claimed in 10,758,549, additional patents could cover specific drug delivery devices, formulations for different routes of administration, or combinations with other active ingredients.
- Method of Use Patents: As seen in 10,758,549, methods of treating specific diseases are patented. This creates a layered protection strategy where even if a generic company can produce the API and a formulation, they may be prevented from marketing it for the patented indications.
Key Competitors and Generic Filings:
As of late 2023/early 2024, lumateperone (marketed as Caplyta) is still under patent protection for its primary indications. Generic manufacturers typically begin filing Abbreviated New Drug Applications (ANDAs) when they believe they can invalidate or design around existing patents, or when patents are nearing expiration.
The primary challenge for generic entrants would be to overcome the patent protection offered by key patents like 10,758,549, particularly the claims to specific crystalline forms and method of use. Patent litigation is common in this space, with brand manufacturers defending their patents and generic companies challenging their validity or asserting non-infringement.
Patent Expiration Dates:
The expiration of key patents will determine when generic competition can fully enter the market. The expiration dates for lumateperone's intellectual property are staggered.
- U.S. Patent 8,071,600: This patent, covering lumateperone and its use in treating CNS disorders, is a foundational patent. Its term would typically expire around 2027, before potential patent term extensions.
- U.S. Patent 8,921,550: Similar to the above, this patent also covers lumateperone and its use. Its expiration would also be around 2027, subject to extensions.
- U.S. Patent 10,758,549: Protecting lumateperone tosilate Form A, this patent's expiration would be around 2034, before potential patent term extensions.
Patent Term Extensions (PTEs):
PTEs are granted to compensate for patent term lost during the regulatory review process of a new drug. For lumateperone products, PTEs can extend the effective patent life for key patents. The eligibility and duration of PTEs depend on specific regulations and the time spent in regulatory review.
Key Takeaways for R&D and Investment Decisions:
- Patent 10,758,549 provides layered protection: It covers not just the tosilate salt but also a specific crystalline form (Form A) and its use in treating major CNS disorders. This makes it challenging for generic manufacturers.
- Generic entry timeline is driven by multiple patents: While foundational composition of matter patents expire earlier, patents like 10,758,549 on specific forms and uses extend market exclusivity well into the next decade, especially with potential patent term extensions.
- Polymorph and salt form patents are critical: Intra-Cellular Therapies, Inc. has strategically patented specific crystalline forms of lumateperone tosilate, creating significant barriers to entry for generic competitors who would need to demonstrate non-infringement or invalidity of these claims.
- Method of use claims extend market control: Even if generic manufacturers can produce a non-infringing form of the API, the method of use claims in patents like 10,758,549 can prevent them from marketing the product for the approved indications.
- Ongoing patent landscape monitoring is essential: Investors and R&D teams must track the expiration of all relevant patents, including those for the base molecule, specific salt forms, crystalline polymorphs, formulations, and methods of use, to accurately forecast market entry of generics.
Frequently Asked Questions
- What is the primary innovation protected by U.S. Patent 10,758,549?
The primary innovation is the crystalline form of lumateperone tosilate designated as Form A, and its pharmaceutical compositions and methods of treating central nervous system disorders.
- How long is the patent protection likely to last for lumateperone tosilate Form A?
The patent itself expires in 2034, but this term can be extended by Patent Term Extensions (PTEs) due to regulatory review periods, potentially pushing the effective expiration date further.
- Can a generic competitor market lumateperone tosilate if they use a different crystalline form?
This depends on the specific claims of other patents. If other patents cover different crystalline forms, or if the use of lumateperone tosilate in general is covered by other patents, a different crystalline form might still infringe upon those. Patent 10,758,549 specifically protects Form A.
- What are the main CNS disorders treated by lumateperone tosilate as claimed in this patent?
The patent claims methods for treating schizophrenia, bipolar depression, and major depressive disorder.
- Are there any other significant patents related to lumateperone that an R&D or investment decision must consider?
Yes, foundational composition of matter patents (e.g., U.S. Patent 8,071,600 and U.S. Patent 8,921,550) covering lumateperone itself, as well as potential future patents on new formulations, delivery methods, or combination therapies, must be considered.
Cited Sources
[1] Intra-Cellular Therapies, Inc. (2022). LUMATEPERONE TOSYLATE AND USE THEREOF (U.S. Patent No. 10,758,549). United States Patent and Trademark Office.
[2] Intra-Cellular Therapies, Inc. (2011). Lumateperone and use thereof (U.S. Patent No. 8,071,600). United States Patent and Trademark Office.
[3] Intra-Cellular Therapies, Inc. (2015). Lumateperone and use thereof (U.S. Patent No. 8,921,550). United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
